UHT Stock Analysis: Universal Health Realty | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 522m USD | 12M Return: 14.5% | US91359E1055 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.82M
EPS Trend: 61.1%
Rev. Trend: 78.8%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Universal Health Realty Income Trust (NYSE: UHT) is a real estate investment trust (REIT) that invests in healthcare and human-service facilities, including acute care hospitals, behavioral healthcare facilities, rehabilitation hospitals, sub-acute care facilities, surgery centers, childcare centers, and medical office buildings. The Trust holds seventy-seven investments across twenty-one states and is headquartered in King of Prussia, Pennsylvania. It was incorporated in Maryland in 1986 and went public in November 1987.
As a healthcare-focused REIT, UHT operates within the Real Estate sector and is classified under the Health Care REITs sub-industry. REITs are generally required to distribute the majority of their taxable income to shareholders as dividends, and healthcare REITs typically generate revenue through long-term leases with hospital operators and medical service providers.
- Fed rate cuts lower borrowing costs for healthcare facility acquisitions
- UHS tenant concentration risk drives occupancy and rental income volatility
- Aging US population lifts demand for medical office buildings
| Net Income: 19.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.07 > 1.0 |
| NWC/Revenue: -243.3% < 20% (prev 7.61%; Δ -250.9% < -1%) |
| CFO/TA 0.09 > 3% & CFO 48.3m > Net Income 19.3m |
| Net Debt (399.7m) to EBITDA (64.8m): 6.16 < 3 |
| Current Ratio: 0.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.9m) vs 12m ago 0.18% < -2% |
| Gross Margin: 76.10% > 18% (prev 94.39%; Δ -18.29% > 0.5%) |
| Asset Turnover: 26.10% > 50% (prev 17.20%; Δ 8.90% > 0%) |
| Interest Coverage Ratio: 1.31 > 6 (EBIT TTM 36.2m / Interest Expense TTM 27.6m) |
| A: -0.64 (Total Current Assets 19.5m - Total Current Liabilities 381.5m) / Total Assets 567.1m |
| B: -0.23 (Retained Earnings -131.4m / Total Assets 567.1m) |
| C: 0.06 (EBIT TTM 36.2m / Avg Total Assets 570.1m) |
| D: 0.34 (Book Value of Equity 143.9m / Total Liabilities 423.2m) |
| Altman-Z'' = -4.16 = D |
| DSRI: 0.66 (Receivables 97.2m/97.8m, Revenue 148.8m/98.6m) |
| GMI: 1.24 (GM 94.39% / 76.10%) |
| AQI: 1.00 (AQ_t 0.95 / AQ_t-1 0.95) |
| SGI: 1.51 (Revenue 148.8m / 98.6m) |
| TATA: -0.05 (NI 19.3m - CFO 48.3m) / TA 567.1m) |
| Beneish M = -2.73 (Cap -4..+1) = A |
As of October 17, 2026, the stock is trading at USD 38.15 with a total of 120,003 shares traded. Over the past week, the price has changed by +1.54%, over one month by -4.72%, over three months by -11.23% and over the past year by +14.48%.
Current recommended Stop Loss: 36.80 (which is 3.5% or 1.5 ATR below the current price).
Universal Health Realty has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold UHT.
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44 | 15.3% |
P/E Trailing = 27.0288
P/E Forward = 38.7597
P/S = 5.1622
P/B = 3.7599
P/EG = 0.6292
Revenue TTM = 148.8m USD
EBIT TTM = 36.2m USD
EBITDA TTM = 64.8m USD
Long Term Debt = 18.1m USD (from longTermDebt, last quarter)
Short Term Debt = 365.6m USD (from shortLongTermDebt, last quarter)
Debt = 406.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.4m
Net Debt = 399.7m USD (calculated: Debt 406.5m - CCE 6.82m)
Enterprise Value = 921.9m USD (522.2m + Debt 406.5m - CCE 6.82m)
Interest Coverage Ratio = 1.31 (Ebit TTM 36.2m / Interest Expense TTM 27.6m)
EV/FCF = 19.10x (Enterprise Value 921.9m / FCF TTM 48.3m)
FCF Yield = 5.23% (FCF TTM 48.3m / Enterprise Value 921.9m)
FCF Margin = 32.43% (FCF TTM 48.3m / Revenue TTM 148.8m)
Net Margin = 12.95% (Net Income TTM 19.3m / Revenue TTM 148.8m)
Gross Margin = 76.10% ((Revenue TTM 148.8m - Cost of Revenue TTM 35.6m) / Revenue TTM)
Gross Margin QoQ = 8.71% (prev 70.59%)
Tobins Q-Ratio = 1.63 (Enterprise Value 921.9m / Total Assets 567.1m)
Interest Expense / Debt = 6.78% (Interest Expense 27.6m / Debt 406.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 28.6m (EBIT 36.2m * (1 - 21.00%))
Current Ratio = 0.05 (Total Current Assets 19.5m / Total Current Liabilities 381.5m)
Debt / Equity = 2.82 (Debt 406.5m / totalStockholderEquity, last quarter 143.9m)
Debt / EBITDA = 6.16 (Net Debt 399.7m / EBITDA 64.8m)
Debt / FCF = 8.28 (Net Debt 399.7m / FCF TTM 48.3m)
Total Stockholder Equity = 150.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.38% (Net Income 19.3m / Total Assets 567.1m)
RoE = 12.79% (Net Income TTM 19.3m / Total Stockholder Equity 150.7m)
RoCE = 21.45% (EBIT 36.2m / Capital Employed (Equity 150.7m + L.T.Debt 18.1m))
RoIC = 15.88% (NOPAT 28.6m / Invested Capital 180.1m)
WACC = 5.69% (E(522.2m)/V(928.7m) * Re(5.95%) + D(406.5m)/V(928.7m) * Rd(6.78%) * (1-Tc(0.21)))
Discount Rate = 5.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.77 | Cagr: 0.17%
[DCF] Terminal Value 75.41% ; FCFF base≈48.3m ; Y1≈48.4m ; Y5≈51.1m
[DCF] Fair Price = 28.47 (EV 795.4m - Net Debt 399.7m = Equity 395.7m / Shares 13.9m; r=8.35% [WACC [floored]]; 5y FCF grow -0.19% → 2.50% )
EPS Correlation: 61.13 | EPS CAGR: 8.77% | SUE: N/A | # QB: 0
Revenue Correlation: 78.83 | Revenue CAGR: 18.04% | SUE: 0.02 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+0.3%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+5.2%